Republic of Korea-based biosimilar developer Celltrion, maker of Inflectra, has announced that it will launch a contract development and manufacturing business to develop novel agents alongside its biosimilar pipeline.
Republic of Korea-based biosimilar developer Celltrion, maker of Inflectra, has announced that it will launch a contract development and manufacturing business to develop novel agents alongside its biosimilar pipeline.
Celltrion said in a statement that the new undertaking will allow the company to collaborate and partner with research institutes and biotechnology firms to successfully commercialize innovative molecules, and partners would benefit from sharing in Celltrion’s accumulated development expertise.
The new effort will focus initially on the therapeutic areas that have “the greatest synergy with Celltrion’s portfolio,” namely inflammatory diseases, cancer, and cardiovascular disease.
The news follows closely on the heels of another announcement concerning partnerships for Celltrion; on May 30, 2018, the company signed an agreement with Yonsei University Health System (which includes 4 hospitals that serve 3 million outpatients and 1 million inpatients each year) to jointly develop and license fc-saxatilin, a proposed therapy for the treatment of ischemic stroke.
Saxatilin is a snake venom that exerts thrombolytic and antiplatelet effects by interacting with multiple integrins on platelets. The researchers developing the drug believe that fc-saxatilin, an Fc-fusion protein, could prevent vascular leakage in patients with ischemic stroke by regulating occludin expression in endothelial tight junctions.1
Celltrion expects that the market for drugs targeting ischemic stroke will grow by 6.8% per year until 2020, and it hopes that an eventually approved fc-saxatilin could compete with Genentech’s thrombolytic drug, alteplase (Activase), for a share of the market.
A Celltrion executive said in a statement, “In order to bolster our next-generation pipeline, in addition to the development of antibody biosimilars, we have continued efforts to explore platform technologies and new molecules in relation to the development of new biopharmaceuticals and synthetic drugs. Through the agreement with Yonsei University Health System, we will push for open innovation to secure new drug pipelines.”
Reference
1. Choi HJ, Kwon I, Kim NE, et al. Fc-saxatilin suppresses hypoxia-induced vascular leakage by regulating endothelial occludin expression. Thromb Haemost. 2017;117(03): 595-605. doi: 10.1160/TH16-06-0469.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.